Temporin L-derived peptide as a regulator of the acute inflammatory response in zymosan-induced peritonitis

Research output: Contribution to journalArticle

Authors

  • Rosa Bellavita
  • Federica Raucci
  • Francesco Merlino
  • Marialuisa Piccolo
  • Maria Grazia Ferraro
  • Carlo Irace
  • Rita Santamaria
  • Ettore Novellino
  • Paolo Grieco
  • Nicola Mascolo
  • Francesco Maione

Colleges, School and Institutes

External organisations

  • Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131, Naples, Italy.
  • Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131, Naples, Italy. Electronic address: paolo.grieco@unina.it.
  • Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131, Naples, Italy. Electronic address: francesco.maione@unina.it.

Abstract

Antimicrobial peptides (AMPs) are an ancient group of defense molecules distributed in nature being found in mammals, birds, amphibians, insects, plants, and microorganisms. They display antimicrobial as well as immunomodulatory properties. The aim of this study was to investigate, for the first time, the anti-inflammatory activities of two synthetic temporin-L analogues (here named peptide 1 and 2) by an in vivo model of inflammation caused by intraperitoneal sub-lethal dose of zymosan. Our results show that peptide 1 and 2 exert anti-inflammatory activity in vivo in response to zymosan-induce peritonitis. Simultaneous administration of 10 mg/kg of both temporins, with a sub-lethal dose of zymosan (500 mg/kg), significantly rescued mice from the classical hallmarks of inflammation, including leukocyte infiltration and synthesis of inflammatory mediators including IL-6, TNF-α and MCP-1. More importantly, flow cytometry analysis highlighted a selective modulation of infiltrating inflammatory monocytes (defined as B220-/GR1hi-F480hi/CD115+) after peptide 2 treatment. Our results and presented models offer the possibility to test, in a preclinical setting, the potential of temporin analogues as anti-inflammatory agents.

Bibliographic note

Copyright © 2019 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Details

Original languageEnglish
Pages (from-to)109788
Number of pages7
JournalBiomedicine and Pharmacotherapy
Volume123
Early online date25 Dec 2019
Publication statusPublished - Mar 2020

Keywords

  • Antimicrobial peptides, Inflammation, Monocytes, Temporin-L, Zymosan